Bone morphogenetic protein receptor 2 inhibition destabilizes microtubules promoting the activation of lysosomes and cell death of lung cancer cells

Cell Commun Signal. 2021 Sep 25;19(1):97. doi: 10.1186/s12964-021-00743-w.

Abstract

Background: Recent studies have shown that bone morphogenetic protein receptor 2 (BMPR2) regulates cell survival signaling events in cancer cells independent of the BMP type 1 receptor (BMPR1) or the Smad-1/5 transcription factor. Mutations in BMPR2 trafficking proteins leads to overactive BMP signaling, which leads to neurological diseases caused by BMPR2 stabilization of the microtubules. It is not known whether BMPR2 regulates the microtubules in cancer cells and what effect this has on cell survival. It is also not known whether alterations in BMPR2 trafficking effects activity and response to BMPR2 inhibitors.

Methods: We utilized BMPR2 siRNA and the BMP receptor inhibitors JL5 and Ym155, which decrease BMPR2 signaling and cause its mislocalization to the cytoplasm. Using the JL5 resistant MDA-MD-468 cell line and sensitive lung cancer cell lines, we examined the effects of BMPR2 inhibition on BMPR2 mislocalization to the cytoplasm, microtubule destabilization, lysosome activation and cell survival.

Results: We show that the inhibition of BMPR2 destabilizes the microtubules. Destabilization of the microtubules leads to the activation of the lysosomes. Activated lysosomes further decreases BMPR2 signaling by causing it to mislocalizated to the cytoplasm and/or lysosome for degradation. Inhibition of the lysosomes with chloroquine attenuates BMPR2 trafficking to the lysosome and cell death induced by BMPR2 inhibitors. Furthermore, in MDA-MD-468 cells that are resistant to JL5 induced cell death, BMPR2 was predominately located in the cytoplasm. BMPR2 failed to localize to the cytoplasm and/or lysosome following treatment with JL5 and did not destabilize the microtubules or activate the lysosomes.

Conclusions: These studies reveal that the inhibition of BMPR2 destabilizes the microtubules promoting cell death of cancer cells that involves the activation of the lysosomes. Resistance to small molecules targeting BMPR2 may occur if the BMPR2 is localized predominantly to the cytoplasm and/or fails to localize to the lysosome for degradation. Video Abstract.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Bone Morphogenetic Protein Receptors, Type I / genetics
  • Bone Morphogenetic Protein Receptors, Type II / antagonists & inhibitors
  • Bone Morphogenetic Protein Receptors, Type II / genetics*
  • Cell Death / drug effects*
  • Cell Death / genetics
  • Cell Proliferation / drug effects*
  • Cell Survival / drug effects
  • Humans
  • Imidazoles / pharmacology
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Lysosomes / drug effects
  • Lysosomes / genetics
  • Microtubules / drug effects
  • Microtubules / genetics
  • Naphthoquinones / pharmacology
  • Pyrazoles / pharmacology
  • Pyrimidines / pharmacology
  • Quinolones / pharmacology
  • RNA, Small Interfering / pharmacology
  • Signal Transduction / drug effects

Substances

  • BMP receptor inhibitor JL5
  • Imidazoles
  • Naphthoquinones
  • Pyrazoles
  • Pyrimidines
  • Quinolones
  • RNA, Small Interfering
  • BMPR1A protein, human
  • BMPR2 protein, human
  • Bone Morphogenetic Protein Receptors, Type I
  • Bone Morphogenetic Protein Receptors, Type II
  • sepantronium